QSI

4 - Quantum-Si Inc (0001816431) (Issuer)

4 - Quantum-Si Inc (0001816431) (Issuer)

144 - Quantum-Si Inc (0001816431) (Subject)

144 - Quantum-Si Inc (0001816431) (Subject)

Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will report financial results for the first quarter 2026 on Thursday, May 7, 2026. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individua

Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that there will be two customer posters presented at the American Association of Cancer Research (AACR) annual meeting on April 17-22, 2026 in San Diego, California. Poster 2421; April 20, 2026 Primary Author: Nigel O'Neil, PhD Poster Title: Combining deep mutational scanning and next-generation protein sequencing to harness dominant protein variants to develop DNA repair inhibitors In the first poster, the researchers describe a complementary genetic (high throughput screens) and proteomic (benchtop pro

Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced a new manuscript available via pre-print on bioRxiv from researchers out of the University of British Columbia and the B.C. Cancer Research Institute. In the pre-print titled "Heterologous expression of the human cohesin complex in Saccharomyces cerevisiae results in a dominant-negative phenotype", the researchers expressed key human chromosome‑organizing proteins (called cohesins) in yeast cells. They hypothesized that the human cohesins were forming complexes and disrupting the activity of endogenous yea

Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that the Compensation Committee of Quantum-Si's Board of Directors has granted 61,439 restricted stock units ("RSUs") to new employees under the Company's previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the "2023 Inducement Plan"). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4). The 2023 Inducement Plan is used exclusively for the grant of equity awards to

Sequencing Results Utilizing a Proteus Prototype System Exceeds Platinum® Pro Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced that the Company has completed the sequencing of multiple samples provided by an existing Platinum Pro customer on a Proteus prototype system. The testing included sequencing the samples on both Platinum Pro and a Proteus prototype system. For Platinum Pro, the Company used the commercially available Version 3 Library Preparation Kit and Version 4 Sequencing Kit. For the Proteus prototype, the Company used the Versio

Multi-city Roadshow To Drive Awareness of Proteus and Develop Customer Funnel for Commercial Launch Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced the start of a roadshow designed to accelerate the education of the market on its Proteus platform and applications for protein sequencing. The roadshow will include information about the Proteus platform and application focus as well as presentations from existing customers on applications for protein sequencing utilizing the Company's first-generation Platinum® Pro instrument. The first roadshow event

DEFA14A - Quantum-Si Inc (0001816431) (Filer)

DEF 14A - Quantum-Si Inc (0001816431) (Filer)

4 - Quantum-Si Inc (0001816431) (Issuer)

4 - Quantum-Si Inc (0001816431) (Issuer)

4 - Quantum-Si Inc (0001816431) (Issuer)

4 - Quantum-Si Inc (0001816431) (Issuer)

144 - Quantum-Si Inc (0001816431) (Subject)

144 - Quantum-Si Inc (0001816431) (Subject)

4 - Quantum-Si Inc (0001816431) (Issuer)

4 - Quantum-Si Inc (0001816431) (Issuer)

4 - Quantum-Si Inc (0001816431) (Issuer)

4 - Quantum-Si Inc (0001816431) (Issuer)

Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that the Compensation Committee of Quantum-Si's Board of Directors has granted 88,781 restricted stock units ("RSUs") to new employees under the Company's previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the "2023 Inducement Plan"). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4). The 2023 Inducement Plan is used exclusively for the grant of equity awards

4 - Quantum-Si Inc (0001816431) (Issuer)

4 - Quantum-Si Inc (0001816431) (Issuer)